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Abstract. High expression levels of glucose transporter 
isoform 1 (GLUT1) and Ki-67 are reportedly associated with 
malignancy-related clinicopathological factors in malignant 
tumors. Recently, a new histological IASLC/ATS/ERS classi-
fication for lung adenocarcinoma was proposed. In this study, 
we investigated the clinicopathological impact of GLUT1 
and Ki-67 expression on early-stage lung adenocarcinoma 
classified according to the IASLC/ATS/ERS classification. 
One hundred and five patients with completely resected 
stage IA lung adenocarcinoma were retrospectively classified 
into two groups, a ʻnon-invasive typeʼ (n=31) or an ʻinvasive 
typeʼ (n=74), based on the IASLC/ATS/ERS classification. 
GLUT1 and Ki-67 expression status was evaluated using 
immunohistochemistry. The epidermal growth factor receptor 
(EGFR) and KRAS mutation status was determined using 
PCR-based assays. Positive GLUT1 and Ki-67 expression 
and EGFR and KRAS mutations were detected in 28 (27%), 
33 (31%), 51 (49%) and 5 (8%) cases, respectively. Positive 
GLUT1 expression was significantly associated with a wild-
type EGFR and mutant KRAS status. A multivariate analysis 
revealed that positive GLUT1 expression was independently 
associated with the ʻinvasive type .ʼ In multivariate analyses for 
overall survival (OS) and disease-free survival (DFS), positive 
Ki-67 and GLUT1 expression was the only independent factor 
for a poor OS (P=0.012) and DFS (P=0.040), respectively. In 
addition, when stratified according to the GLUT1 and Ki-67 
status, double-positive cases had the poorest DFS and OS 
times, compared with the other categories. Positive GLUT1 
expression is associated with the invasive character of early-
stage lung adenocarcinoma and with early disease relapse. Our 
results strongly suggest that GLUT1 and Ki-67 play important 
roles in acquiring biological malignant potential in early-stage 
lung adenocarcinoma.
Introduction
Lung cancer is the leading cause of cancer-related mortality 
worldwide (1,2). Lung adenocarcinoma is the most common 
type of lung cancer, and its incidence has increased in recent 
years (3). Surgical resection is the treatment of first choice 
for early-stage lung adenocarcinoma, but the 5-year overall 
survival (OS) rate remains at ~80% for stage IA disease (4). 
Understanding the histological and biological character of 
early-stage lung adenocarcinoma is important for improving 
the clinical outcome of this patient population.
Cancer cells often have higher rates of glucose metabo-
lism than normal cells, producing lactic acid rather than 
catabolizing glucose via the tricarboxylic acid (TCA) 
cycle (5). The glucose transporter family is a collection of 
membrane proteins that are responsible for glucose uptake. 
Glucose transporter isoform 1 (GLUT1) is expressed in the 
brain and in erythrocytes (6). GLUT1 also maintains a basal 
level of glucose uptake in most cell types under hypoxic and 
hypoglycemic conditions. The overexpression of GLUT1 has 
been observed in many types of human malignancies (7,8). In 
non-small cell lung cancers (NSCLC), the overexpression of 
GLUT1 is reportedly associated with a poor prognosis (9,10). 
As a classical marker of proliferation, the Ki-67 protein is well 
known to be present in nuclei during the active phase of the 
cell cycle (11-13), and the overexpression of Ki-67 is a prog-
nostic marker in many types of cancer (14,15). A high Ki-67 
labeling index reportedly predicts poor prognosis in stage I 
NSCLCs (16-19).
Since 2004, the role of activating mutations of epidermal 
growth factor receptor (EGFR) and KRAS genes as character-
istic somatic mutations in lung adenocarcinoma has become 
a topic of interest, since these mutations exhibit a mutually 
exclusive relationship and have clinical implications [i.e., EGFR 
mutations are associated with responsiveness to EGFR tyrosine 
kinase inhibitors (EGFR-TKIs)] (20-22).
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An international multidisciplinary classification for lung 
adenocarcinoma was recently proposed by the International 
Association for the Study of Lung Cancer (IASLC), the 
American Thoracic Society (ATS), and the European 
Respiratory Society (ERS) (23). This new classification (the 
IASLC/ATS/ERS classification) provides uniform termi-
nology and diagnostic criteria especially for adenocarcinoma 
with lepidic growth which was formerly classified as bron-
chioloalveolar carcinoma (BAC), as the definition of BAC was 
unclear in the previous classification (24). The term BAC has 
been used for a broad spectrum of tumors including solitary 
small non-invasive peripheral lung tumors, invasive adeno-
carcinomas with minimal invasion, mixed subtype invasive 
adenocarcinomas, mucinous and nonmucinous subtypes 
of tumors and widespread advanced disease; the clinical 
outcome of patients with BAC has also varied. In the new clas-
sification, lung adenocarcinomas are classified into four major 
categories based on tumor invasiveness: i) preinvasive lesions, 
ii) minimally invasive adenocarcinoma (MIA), iii) invasive 
adenocarcinoma, and iv) variants of invasive adenocarcinoma. 
Invasive adenocarcinoma is the most common type among 
surgically resected specimens and is subdivided into five 
types according to semiquantitative subtype patterns, rather 
than using the term adenocarcinoma, mixed subtype. Notably, 
patients with preinvasive lesions or MIAs are expected to have 
a 100% or nearly 100% OS following complete resection, 
suggesting that this new classification may be useful for deter-
mining suitable therapeutic strategies and predicting patient 
outcome.
In this study, we investigated the clinicopathological 
impact of GLUT1 and Ki-67 expression levels on early-stage 
lung adenocarcinoma classified according to the IASLC/ATS/
ERS classification.
Materials and methods
Patients. We reviewed patients with lung adenocarcinoma who 
had undergone complete resections at Okayama University 
Hospital between January 2004 and December 2006. A total 
of 133 consecutive patients with pathologic stage IA disease, 
according to the International Union Against Cancer's TNM 
classification for malignant tumors (25), underwent complete 
tumor resection. Among them, patients with recurrent tumor 
or second primary lung adenocarcinoma were excluded. As a 
result, 105 patients with stage IA lung adenocarcinoma were 
eligible for this study. The follow-up protocol after surgery 
was as follows: chest and abdominal computed tomography 
(CT) or positron emission tomography/CT scan and enhanced 
brain magnetic resonance imaging were repeated every six 
months for three years. After three years, a chest X-ray was, in 
principle, repeated ever year and additional examinations were 
performed as necessary.
Histological classification and immunohistochemistry for 
GLUT1 and Ki-67. Two investigators (K.I. and Y.M.) who 
were unaware of the clinical data independently classified all 
the tumors according to the IASLC/ATS/ERS classification 
and discussed the final diagnosis in cases with diagnostic 
discrepancies. The written informed consent of each patient 
and the permission of the Institutional Review Board were 
obtained. This study was approved by the Ethics Committee 
of Okayama University (approval no. 478).
For the immunohistochemistry (IHC), 4-µm sections were 
cut from paraffin-embedded tissue specimens on MAS-GP 
type A coated glass slides (S-9901; Matsunami Glass Ind., 
Ltd., Osaka, Japan). The slides were deparaffinized in xylene 
and rehydrated in a graded series of ethanol (100, 100, 90, 70 
and 50%). After revealing antigens with 10 mM of sodium 
citrate (pH 6.0), the slides were incubated in 3% H2O2 for 
10 min to block endogenous peroxidase. To inhibit non-specific 
binding, the samples were incubated in diluted normal horse 
serum for 30 min. After blocking, the slides were incubated 
with GLUT1 (Abcam, Cambridge, UK; diluted 1:200 in PBS) 
and Ki-67 (Novocastra, Newcastle, UK; diluted 1:2,000 in 
PBS) antibodies at 4˚C overnight. The slides were washed in 
PBS for 5 min and incubated in secondary antibody for 30 min 
at room temperature (ImmPRESS Anti-Rabbit Ig peroxidase 
Polymer Detection kit; Vector Laboratories, Peterborough, 
UK). The slides were stained with 3,3'-diaminobenzidine (DAB 
Substrate kit; Vector Laboratories), and were counterstained in 
Mayer's hematoxylin. Tumor cells were considered positive for 
GLUT1 if the cell membrane staining was no less than that of 
the erythrocytes in the same section. GLUT1 expression was 
considered positive in each section if the percentage of tumor 
cells with positive staining was >10%, as previously reported 
(7,26,27). Ki-67 staining was evaluated using the labeling 
index (28,29). In the area with the strongest Ki-67 staining, 
positively stained cells were defined as having a clearly stained 
nucleus and the Ki-67 labeling index was considered positive 
when >15% of the tumor cells were stained among at least 
1,000 tumor cells (30-32).
DNA extraction and mutation analyses of EGFR and KRAS 
genes. DNA was extracted from formalin-fixed and paraffin-
embedded tissues (n=51) or frozen tissues (n=54) using the 
QIAamp® DNA FFPE Tissue kit (Qiagen, Hilden, Germany) or 
by digestion with proteinase K, followed by phenol-chloroform 
(1:1) extraction and ethanol precipitation, respectively. EGFR 
mutational status was determined using a mutant non-enriched 
PCR assay, as previously reported (33). KRAS mutations at 
codons 12 and 13 were examined using PCR-based direct 
sequencing using an ABI PRISM 3130xl Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA), as previously 
reported (34,35).
Statistical analysis. Differences between the two groups were 
assessed using χ2 tests or Fisher's exact test, as appropriate. 
Multiple logistic regression analyses were used to identify 
independent factors and to adjust for the influence of other 
co-variables. The OS and disease-free survival (DFS) periods 
were calculated from the date of operation until the date of 
death or the last follow-up for the OS and until confirmed 
disease recurrence based on cross-sectional imaging studies 
or death for the DFS.
A univariate analysis of the OS and DFS was performed 
using the Kaplan-Meier method and the log-rank test. A multi-
variate analysis for OS and DFS was performed using the Cox 
proportional-hazards model. The stepwise procedure was used 
to select independent variables using a backward elimination 
method with P-values of 0.10 for entry and 0.15 for rejection. 
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All the data were analyzed using the JMP, version 9.0.0 (SAS 
Institute Inc., Cary, NC, USA).
Results
Patient characteristics. The patient characteristics are shown 
in Table I. The median age was 65 years (range, 29-83 years); 
49 patients were men, and 56 were women. The smoking 
categories were defined as follows: never-smokers, those with 
a lifetime exposure of ≤100 cigarettes; and ever-smokers, 
those with a lifetime exposure of >100 cigarettes. Eighty-eight 
patients underwent a lobectomy, while a segmentectomy or 
wedge resection was performed for 17 tumors exhibiting a 
pure ground glass opacity during CT imaging. We defined 
these cases as curative operations since none of the 17 cases 
experienced disease relapse.
IASLC/ATS/ERS classification of lung adenocarcinoma. 
The details of the lung adenocarcinoma subtypes according 
to the IASLC/ATS/ERS classification are shown in Table I. 
Among the four categories, invasive adenocarcinoma (n=69, 
65.7%) was the most frequent diagnosis in this study. Among 
the invasive adenocarcinomas, 63.8% would have been diag-
nosed as mixed subtype, according to the 2004 World Health 
Organization classification (24). Since adenocarcinoma in situ 
(AIS) and minimally invasive adenocarcinoma (MIA) with a 
diameter equal to 2 cm or less have previously been reported to 
have a 5-year OS or DFS rate of 100% (36,37), we defined these 
tumors as ‘non-invasive type’ (n=31) and compared them with 
the other ‘invasive type’ (n=74) adenocarcinomas, including 
invasive adenocarcinoma and invasive mucinous adenocarci-
noma. We then performed further analyses comparing those 
two groups.
Molecular alterations in clinical samples. The results and 
representative samples of the IHC staining patterns for GLUT1 
and Ki-67 are shown in Table II and Fig. 1. Positive GLUT1 and 
Ki-67 expressions were observed in 28 (26.7%) and 33 (31.4%) 
of the 105 patients, respectively. Among the 105 tumors, we 
detected EGFR mutations in 51 tumors (48.6%). Mutations in 
KRAS codons 12 or 13 were detected in 5 of the 105 tumors 
(8.3%).
The inter-relationships of GLUT1 and Ki-67 expres-
sion levels and EGFR and KRAS mutations were examined. 
Positive GLUT1 expression was significantly more common 
among EGFR wild-type cases (P=0.004), KRAS mutant cases 
(P=0.02), and tumors with positive Ki-67 expression (P=0.003) 
(Table II).
Relationship between molecular alterations and clinicopatho-
logical factors. The associations between the above-mentioned 
molecular alterations and clinical factors are shown in Table ΙΙ. 
Positive GLUT1 expression was significantly more common 
among men (P<0.001), ever smokers (P=0.008), and patients 
with large tumors (T1b) (P=0.009). Positive Ki-67 expres-
sion was significantly more common among men (P<0.001) 
and ever smokers (P=0.005). Mutant EGFR was significantly 
more common among women (P<0.001) and never smokers 
(P=0.002). Mutant KRAS was not significantly associated with 
any clinical factor.
Table I. Patient characteristics.
Subsets n %
Age
  <65   52 49.5
  ≥65   53 50.5
Gender
  Male   49 46.7
  Female   56 53.3
Smoking status
  Never   56 53.3
  Ever   49 46.7
Tumor size
  T1a (≤2 cm)   73 69.5
  T1b (>2 cm)   32 30.5
GLUT1 expression
  Negative   77 73.3
  Positive   28 26.7
Ki-67 expression
  Negative   72 68.6
  Positive   33 31.4
EGFR mutation
  Mutant   51 48.6
  Wild-type   54 51.4
KRAS mutation
  Mutant     5 4.8
  Wild-type 100 95.2
IASLC/ATS/ERS classification
  Preinvasive lesion
    Adenocarcinoma in situ
      Nonmucinous   19 18.1
      Mucinous     0 0.0 
      Mixed mucinous/nonmucinous     0 0.0 
    Minimally invasive adenocarcinoma
      Nonmucinous   12 11.4
      Mucinous     0 0.0
      Mixed mucinous/nonmucinous     0 0.0
    Invasive adenocarcinoma
      Lepidic predominant   18 17.1
      Acinar predominant     1 1.0
      Papillary predominant   45 42.9
      Micropapillary predominant     0 0.0
      Solid predominant with mucin production     5 4.8
    Variants of invasive adenocarcinoma
      Invasive mucinous adenocarcinoma     5 4.8 
      Colloid     0 0.0
      Fetal     0 0.0
      Enteric     0 0.0
GLUT1, glucose transporter isoform 1; EGFR, epidermal growth 
factor receptor.
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Table II. GLUT1 and Ki-67 expression and clinical and genetic factors.
 GLUT1 positive Ki-67 positive EGFR mutant KRAS mutant
 -------------------------------------------- ------------------------------------------------ ------------------------------------------ ---------------------------------------
Subsets n % P-value n % P-value n % P-value n % P-value
Age
  <65 14 26.9 1 14 26.9 0.3 23 44.2 0.8 1 1.9 0.2
  ≥65 14 26.4  19 35.8  28 52.8  4 7.5
Gender
  Male 21 42.9 <0.001 24 49.0 <0.001 15 30.6 <0.001 2 4.1 0.8
  Female   7 12.5    9 16.1  36 64.3  3 5.4
Smoking status
  Never   9 16.1 0.008 11 19.6 0.005 35 62.5 0.002 2 3.6 0.4
  Ever 19 38.8  22 44.9  16 32.7  3 6.1
Tumor size
  T1a (≤2 cm) 14 19.2 0.009 21 28.8 0.4 32 43.8 0.14 3 4.1 0.2
  T1b (>2 cm) 14 43.8  12 37.5  19 59.4  2 6.3
GLUT1 expression
  Negative - - - 18 23.4 0.003 44 57.1 0.004 1 1.3 0.02
  Positive - -  15 53.6    7 25.0  4 14.3
Ki-67 expression
  Negative 13 18.1 0.003 - - - 38 52.8 0.2 2 2.8 0.2
  Positive 15 45.5  - -  13 39.4  3 9.1
EGFR mutation
  Mutant   7 13.7 0.004 20 37.0 0.2 - - - 0 0.0 0.03
  Wild-type 21 38.9  13 25.5  - -  5 9.8
KRAS mutation
  Mutant   4 80.0 0.02 3 60.0 0.2   0 0.0 0.03 - - -
  Wild-type 24 24.0  30 30.0  51 51.0  - -
GLUT1, glucose transporter isoform 1; EGFR, epidermal growth factor receptor.
Figure 1. Representative results of immunohistochemistry for GLUT1 and Ki-67. (A) Negative staining for GLUT1. Erythrocytes were used as an internal posi-
tive control. (B) Positive staining for GLUT1. (C) Negative staining for Ki-67 (labeling index, 2.0%). (D) Positive staining for Ki-67 (labeling index, 29.2%).
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Furthermore, we investigated the relationship between the 
IASLC/ATS/ERS classification and clinical and molecular 
factors (Table ΙΙΙ). ‘Invasive type’ adenocarcinomas were 
more common among patients with large tumors (P=0.01), 
GLUT1 positive tumors (P=0.002), and Ki-67 positive tumors 
(P=0.01). In a multiple logistic regression analysis including 
the significant factors mentioned above, ‘invasive type’ 
adenocarcinomas were only correlated with positive GLUT1 
expression [odds ratio (OR), 4.85; 95% confidence interval 
(CI), 1.21-32.56; P=0.048].
Impact of GLUT1 and Ki-67 expression on clinical 
outcome. As of September 2011, 4 (3.8%) of the 105 patients 
had succumbed and the median follow-up duration was 
59.7 months. Ten (9.5%) patients had experienced disease 
relapse. The 5-year OS rate was 94.6% (95% CI, 86.0-98.0%). 
The 5-year DFS rate was 90.2% (95% CI, 81.9-94.8%). The 
associations between OS or DFS and clinicopathological 
and genetic factors are shown in Table IV. The associations 
between the OS and clinicopathological and genetic factors 
showed that positive Ki-67 expression was the only significant 
factor of a poor OS (P=0.002), although positive GLUT1 
expression and ‘invasive type’ adenocarcinoma tended to be 
correlated with a poor OS (P=0.063 and P=0.098, respec-
tively) according to univariate analysis. In a multivariate 
analysis, Ki-67 was the only independent factor associated 
with a poor OS [hazard ratio (HR), 2.0x107; 95% CI, 2.00-
3.27x1059; P=0.012]. All 10 tumors in patients with disease 
relapse were diagnosed as ‘invasive type’ adenocarcinomas. In 
univariate analyses, a male gender (P=0.02), an ever smoking 
status (P=0.02), an ‘invasive type’ classification (P=0.005), a 
positive GLUT1 expression (P=0.0003), and a positive Ki-67 
expression (P=0.0005) were significantly associated with a 
poor DFS. In a multivariate analysis including the significant 
factors mentioned above, positive GLUT1 expression was the 
only independent predictor of a poor DFS (HR, 6.02; 95% CI, 
1.25-48.22; P=0.040), although positive Ki-67 expression 
tended to correlate with a poor DFS (HR, 6.49; 95% CI, 1.15-
57.53; P=0.058).
We also investigated the impact of the combined effect of 
GLUT1 and Ki-67 expression on OS and DFS. We found that 
patients with positive expression for both GLUT1 and Ki-67 
had a poorer clinical outcome than the other patients (OS, 
P=0.009 and DFS, P<0.0001) (Fig. 2).
Table III. Association between ‘invasive type’ adenocarcinoma 
and clinical and genetic factors.
   Univariate Multivariate
   -------------------- ------------------------
Subsets n % P-value P-value
Age
  <65 37 71.2 0.9
  ≥65 37 69.8
Gender
  Male 37 75.5 0.3
  Female 37 66.1
Smoking status
  Never 36 64.3 0.14
  Ever 38 77.6
Tumor size
  T1a (≤2 cm) 46 63.0 0.01 0.06
  T1b (>2 cm) 28 87.5
GLUT1 expression
  Negative 48 62.3 0.002 0.048
  Positive 26 92.9
Ki-67 expression
  Negative 45 62.5 0.01 0.06
  Positive 29 87.9
EGFR mutation
  Mutant 39 76.5 0.19
  Wild-type 35 64.8
KRAS mutation
  Mutant   4 80.0 1.0
  Wild-type 70 70.0
GLUT1, glucose transporter isoform 1; EGFR, epidermal growth 
factor receptor.
Figure 2. Kaplan-Meier plots of survival rates according to GLUT1 and Ki-67 
expressions. (A) Overall survival of all patients. (B) Disease free survival of 
all patients. The resulting curves were compared using a log-rank test.
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Discussion
In this study, we investigated the expression status of GLUT1 
and Ki-67 in early-stage cases of lung adenocarcinoma clas-
sified according to a new international multidisciplinary 
classification, the IASLC/ATS/ERS classification, and found 
that, i) positive GLUT1 expression was significantly associated 
with a wild-type EGFR and mutant KRAS status, ii) GLUT1 
expression was independently associated with ‘invasive type’ 
adenocarcinomas, and iii) positive GLUT1 expression was 
correlated with positive Ki-67 expression and double positive 
expression was associated with a poor outcome.
We examined the EGFR and KRAS mutations, which are 
key somatic mutations of lung adenocarcinoma, in the patient 
population and analyzed the correlations between the mutation 
status and GLUT1 expression, Ki-67 expression, and histolog-
ical features. The frequent overexpression of GLUT1 in NSCLC 
has been reported in patients with wild-type EGFR and mutant 
KRAS (38). In the present study, we found that positive GLUT1 
expression was frequently observed in lung adenocarcinomas 
without EGFR mutation and in those with KRAS mutation. 
Although the association between the GLUT1 expression level 
and the initiation of these mutations is unknown, low glucose 
environments, which promote GLUT1 expression, have been 
reported as a driving force underlying the development of 
KRAS mutations during colorectal tumorigenesis (39).
Both GLUT1 and Ki-67 are known to be associated 
with tumor invasiveness and proliferation (40). Moreover, 
Noguchi et al (41) reported that small lung adenocarcinomas 
(with a diameter equal to 2 cm or less) with pure or minimally 
invasive ‘BAC’ (Noguchi types A and B) had a 5-year DFS 
of 100% after complete resection as confirmed by subsequent 
Table IV. Cox proportional hazards model for post-operative overall survival and disease-free survival.
 OS DFS
 ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
 Univariate Multivariate Univariate Multivariate
 --------------------------------------- ------------------------------------- -------------------------------------- -------------------------------------
Subsets HR P-value HR P-value HR P-value HR P-value
Age
  <65 0.70 0.7   0.77 0.7
  ≥65
Gender
  Male 3.58 0.2   4.94 0.02 0.32 0.5
  Female
Smoking status
  Never 0.27 0.2   0.19 0.02 0.3 0.4 
  Ever
Tumor size
  T1a (≤2 cm) 1.28 0.8   0.39 0.15
  T1b (>2 cm)
IASLC/ATS/ERS classification
  ‘Non-invasive type’ 4.7x10-7 0.098 1.9x106 0.4 4.4x10-7 0.005 8.4x10-7 0.2
  ‘Invasive type’
GLUT1 expression
  Positive 7.02 0.063 1.82 0.6  11.9 0.0003 6.02 0.040
  Negative
Ki-67 expression
  Positive 1.3x107 0.002 2.0x107 0.012 10.7 0.0005 6.49 0.058
  Negative
EGFR mutation
  Mutant 1.11 0.9   0.91 0.9
  Wild-type
KRAS mutation
  Mutant 2.1x10-6 0.5   0.40 0.4
  Wild-type
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; 95% CI, 95% confidence interval; GLUT1, glucose transporter isoform 1; 
EGFR, epidermal growth factor receptor.
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reports (42,43). The IASLC/ATS/ERS classification has also 
indicated that patients with AIS or MIA have a 100% or nearly 
100% DFS. In this study, we classified AIS and MIA as ‘non-
invasive type’ adenocarcinomas and compared them with 
‘invasive type’ adenocarcinomas; as a result, positive GLUT1 
expression was found to be the only independent factor associ-
ated with ‘invasive’ adenocarcinoma. High expression levels of 
GLUT1 have previously been reported as a significant predictor 
of a poor outcome in 47 cases of stage IA and IB adenocarci-
noma (16). In the present study, we demonstrated that GLUT1 
and Ki-67 were the most significant factors associated with a 
poor clinical outcome with regard to the DFS and OS, respec-
tively. Of interest, GLUT1 and Ki-67 double-positive cases 
had the poorest DFS and OS time, suggesting that this popula-
tion exhibited a high degree of biological malignancy. These 
findings also suggest that these markers may be useful for 
predicting the recurrence of disease after the complete resec-
tion of early-stage lung adenocarcinoma and may be useful for 
the selection of patients requiring adjuvant therapy.
In conclusion, positive GLUT1 expression is frequently 
observed in ‘invasive type’ early-stage lung adenocarcinoma, 
as classified according to the IASLC/ATS/ERS classification. 
Our results strongly suggest that GLUT1, together with Ki-67, 
plays an important role in the acquisition of biological malig-
nant potential in early-stage lung adenocarcinoma.
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